SCHEMBL6441674

SCHEMBL6441674

Cc1ccc(COc2nc(N)nc(-n3cccn3)c2C#N)nc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.46
GABRA1 P14867 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
TLR7 Q9NYK1 5/20 0.35
MBOAT4 Q96T53 1/20 0.35
ADORA1 P30542 2/20 0.35
PDE10A Q9Y233 1/20 0.34
GRM5 P41594 3/20 0.34
NLRP3 Q96P20 3/20 0.33
KCNH2 Q12809 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA2B P29275 1/20 0.32
ATP4A P20648 1/20 0.31
ATP4B P51164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441693 0.85 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6444568 0.84 ADORA2A (0.43) ADORA2ATLR7ADORA1PDE10AGRM5
SCHEMBL6442933 0.83 ADORA2A (0.42) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6441301 0.81 ADORA2A (0.44) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6442519 0.80 MGMT (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6467274 0.77 ADORA2A (0.44) ADORA2AADORA1ATP4AATP4B
SCHEMBL6441954 0.76 ADORA2A (0.46) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL6441608 0.76 ADORA2A (0.41) ADORA2AGABRA1GABRG2GABRB3GABRA5
SCHEMBL5046609 0.73 ADORA2A (0.50) ADORA2AADORA1ADORA2B
SCHEMBL6442743 0.70 ADORA2A (0.35) ADORA2AGABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885GABRA1 64/4885GABRG2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.